Home › Companies › Supernus Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Supernus Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 18, 2026: 5 items on Supernus Pharmaceuticals, Inc.’s Form 8-K, filed June 18, 2026: 5 passed (calculated).
Notable dissent: 1 director (11.6% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Rubric Capital (13F, 3.0%, as of September 30, 2026)
Explore Supernus Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Supernus Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Frederick M. Hudson | 45,058,634 | -- | -- | 2,177,068 | 3,073,181 | 95% | Passed (calculated) | — |
| Elect Director: Charles W. Newhall, III | 41,743,154 | -- | -- | 5,492,548 | 3,073,181 | 88% | Passed (calculated) | — |
| 2. To approve, on a non-binding basis, the compensation paid to our named executive officers | 45,552,633 | 1,675,355 | 7,714 | -- | 3,073,181 | 96% | Passed (calculated) | — |
| 3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026 | 49,882,228 | 417,336 | 9,319 | -- | 0 | 99.2% | Passed (calculated) | — |
| 4. To act upon a proposal to amend the Supernus Pharmaceuticals, Inc | 41,925,692 | 5,302,088 | 7,922 | -- | 3,073,181 | 89% | Passed (calculated) | — |
Source: Supernus Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
376 asset managers disclosed a vote on at least one Supernus Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
Description as filed by funds: to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Charles W. Newhall, III
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Charles W. Newhall, III”): 41,743,154 for, 5,492,548 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 88% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 107 asset managers below reported 22,371,221 for, 1,753,571 withheld, 45 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,583,059 | 0 | 45 | 9,800 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 3,716 | 0 | 0 | 998,212 | Withhold |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 207,993 | Withhold |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 195,218 | 0 | 0 | 0 | For |
| Brighthouse | 168,996 | 0 | 0 | 9,497 | Mixed |
| Lincoln Financial | 136,521 | 0 | 0 | 40,087 | Mixed |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 159,445 | 0 | 0 | 0 | For |
| Empower | 159,079 | 0 | 0 | 0 | For |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 0 | 131,115 | Withhold |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Frederick M. Hudson
Supernus Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Frederick M. Hudson”): 45,058,634 for, 2,177,068 withheld, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 106 asset managers below reported 23,715,749 for, 403,638 withheld, 16 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,583,088 | 0 | 16 | 9,800 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 1,001,850 | 0 | 0 | 78 | For |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 195,218 | 0 | 0 | 0 | For |
| Brighthouse | 168,996 | 0 | 0 | 9,497 | Mixed |
| Lincoln Financial | 172,911 | 0 | 0 | 3,697 | For |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 159,445 | 0 | 0 | 0 | For |
| Empower | 159,079 | 0 | 0 | 0 | For |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 0 | 131,115 | Withhold |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
Showing the 25 largest of 106 asset managers. All 106 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: TO CONSIDER AND ACT UPON A PROPOSAL TO AMEND THE SUPERNUS PHARMACEUTICALS, INC. 2021 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE UNDER THE PLAN.
Supernus Pharmaceuticals, Inc.’s own tally for this item (“4. To act upon a proposal to amend the Supernus Pharmaceuticals, Inc”): 41,925,692 for, 5,302,088 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 110 asset managers below reported 22,106,981 for, 1,969,172 against, 3,810 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,575,557 | 17,346 | 0 | 0 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 2,338 | 999,590 | 0 | 0 | Against |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 0 | 312,681 | 0 | 0 | Against |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 186,124 | 21,276 | 0 | 0 | Mixed |
| GLENMEDE FUND INC | 195,218 | 0 | 0 | 0 | For |
| Brighthouse | 178,493 | 0 | 0 | 0 | For |
| Lincoln Financial | 140,218 | 36,390 | 0 | 0 | Mixed |
| World Funds Trust | 0 | 167,126 | 0 | 0 | Against |
| American Century | 0 | 159,445 | 0 | 0 | Against |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 0 | 152,349 | 0 | 0 | Against |
| JPMorgan | 131,115 | 0 | 0 | 0 | For |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Empower | 118,324 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 96.4% for (June 16, 2025 meeting) unchanged
Description as filed by funds: To approve, on a non-binding basis, the compensation paid to our named executive officers.
Supernus Pharmaceuticals, Inc.’s own tally for this item (“2. To approve, on a non-binding basis, the compensation paid to our named executive officers”): 45,552,633 for, 1,675,355 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Supernus Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives” (2 managers, 52 for).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,592,891 | 12 | 0 | 0 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 1,001,928 | 0 | 0 | 0 | For |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 195,218 | 0 | 0 | 0 | For |
| Brighthouse | 168,996 | 9,497 | 0 | 0 | Mixed |
| Lincoln Financial | 172,911 | 3,697 | 0 | 0 | For |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 0 | 159,445 | 0 | 0 | Against |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 131,115 | 0 | 0 | Against |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Empower | 118,324 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
Fund voting reports, all 108 managers: 23,571,466 for, 507,676 against, 3,810 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 2,395,465 | 878 | 0 | 0 | For |
| State Street | 2,178,524 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1,829,285 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 1,533,481 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,489,631 | 0 | 0 | 0 | For |
| Loomis Sayles | 1,248,354 | 0 | 0 | 0 | For |
| Stephens Investment Management Group LLC | 1,168,784 | 0 | 0 | 0 | For |
| Renaissance | 1,108,266 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 21,276 | 0 | 0 | 0 | For |
| Citadel | 861,525 | 0 | 0 | 0 | For |
| Charles Schwab | 708,058 | 0 | 0 | 0 | For |
| Northern Trust | 590,556 | 0 | 0 | 0 | For |
| ASHFORD CAPITAL MANAGEMENT INC | 570,444 | 0 | 0 | 0 | For |
| Sofinnova Investments, Inc. | 568,124 | 0 | 0 | 0 | For |
| Vanguard | 467,650 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 454,625 | 0 | 0 | 0 | For |
| Victory Capital | 407,806 | 0 | 0 | 0 | For |
| Woodline Partners LP | 407,024 | 0 | 0 | 0 | For |
| RICE HALL JAMES & ASSOCIATES, LLC | 402,454 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 341,601 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 338,223 | 0 | 0 | 0 | For |
| Freestone Grove Partners LP | 275,956 | 0 | 0 | 0 | For |
| MetLife Investment Management, LLC | 261,601 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 254,546 | 0 | 0 | Against |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 229,712 | 1,855 | 0 | 0 | For |
Institutional-manager reports, all 292 managers: 25,392,027 for, 841,740 against, 359 not voted, 877,834 mixed. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.2% Majority: yes · of votes cast
Prior year: 99.4% for (June 16, 2025 meeting) ▼ 0.2 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Supernus Pharmaceuticals, Inc.’s own tally for this item (“3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2026”): 49,882,228 for, 417,336 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 107 asset managers below reported 24,120,946 for, 81 against, 3,810 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,592,900 | 3 | 0 | 0 | For |
| BlackRock | 6,118,015 | 0 | 0 | 0 | For |
| Fidelity | 1,534,156 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 1,453,096 | 0 | 0 | 0 | For |
| State Street | 1,001,850 | 78 | 0 | 0 | For |
| Dimensional | 655,165 | 0 | 0 | 0 | For |
| Charles Schwab | 637,184 | 0 | 0 | 0 | For |
| Loomis Sayles | 531,254 | 0 | 0 | 0 | For |
| Invesco | 335,993 | 0 | 0 | 0 | For |
| AMG FUNDS | 312,681 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 258,628 | 0 | 0 | 0 | For |
| Victory Capital | 245,103 | 0 | 0 | 0 | For |
| TIAA | 207,993 | 0 | 0 | 0 | For |
| Goldman Sachs | 207,400 | 0 | 0 | 0 | For |
| GLENMEDE FUND INC | 195,218 | 0 | 0 | 0 | For |
| Brighthouse | 178,493 | 0 | 0 | 0 | For |
| Lincoln Financial | 176,608 | 0 | 0 | 0 | For |
| World Funds Trust | 167,126 | 0 | 0 | 0 | For |
| American Century | 159,445 | 0 | 0 | 0 | For |
| Empower | 159,079 | 0 | 0 | 0 | For |
| First Trust | 155,293 | 0 | 0 | 0 | For |
| THIRD AVENUE TRUST | 152,349 | 0 | 0 | 0 | For |
| JPMorgan | 131,115 | 0 | 0 | 0 | For |
| John Hancock | 119,425 | 0 | 0 | 0 | For |
| Royce | 111,276 | 0 | 0 | 0 | For |
Showing the 25 largest of 107 asset managers. All 107 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 58,039,721 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.36% |
| 2 | BlackRock | 10.54% |
| 3 | Fidelity | 2.64% |
| 4 | Delaware/Macquarie | 2.50% |
| 5 | State Street | 1.73% |
| 6 | Dimensional | 1.13% |
| 7 | Charles Schwab | 1.10% |
| 8 | Loomis Sayles | 0.92% |
| 9 | Invesco | 0.58% |
| 10 | AMG FUNDS | 0.54% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 4.13% |
| 2 | State Street | 3.75% |
| 3 | NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 3.15% |
| 4 | ARMISTICE CAPITAL, LLC | 2.64% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.57% |
| 6 | Loomis Sayles | 2.15% |
| 7 | Stephens Investment Management Group LLC | 2.01% |
| 8 | Renaissance | 1.91% |
| 9 | GW&K Investment Management, LLC | 1.55% |
| 10 | Citadel | 1.48% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 8,797,254 | 15.16% | Form 13F, quarter ended March 31, 2026 |
| BlackRock, Inc. and its affiliates | 8,197,023 | 14.12% | Proxy statement (DEF 14A), table as of April 29, 2026 |
| Vanguard Group | 6,048,496 | 10.42% | Form 13F, quarter ended March 31, 2026 |
| Jack A. Khattar + | 3,934,409 | 6.78% | Proxy statement (DEF 14A), table as of April 29, 2026 |
| Millennium Management | 3,315,973 | 5.71% | Form 13F, quarter ended March 31, 2026 |
| Millenium Management LLC and its affiliates | 3,281,615 | 5.65% | Proxy statement (DEF 14A), table as of April 29, 2026 |
| Vanguard Portfolio Management | 3,263,309 | 5.62% | Schedule 13G, filed April 29, 2026 |
| Armistice Capital, LLC | 2,764,000 | 4.76% | Proxy statement (DEF 14A), table as of April 29, 2026 |
| Dimensional Fund Advisors LP | 2,712,341 | 4.67% | Proxy statement (DEF 14A), table as of April 29, 2026 |
| State Street | 2,288,127 | 3.94% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 58,039,721 shares outstanding, as reported by Supernus Pharmaceuticals, Inc. on its Form 10-Q dated April 28, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Supernus Pharmaceuticals, Inc.'s shareholder meeting held June 18, 2026, in the 2025-2026 proxy season, 376 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,326 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding basis, the compensation paid to our named executive officers. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Supernus Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Supernus Pharmaceuticals, Inc.’s 10-Q dated April 28, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Supernus Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Supernus Pharmaceuticals, Inc. 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/supernus-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.